Rigel Pharmaceuticals’ Tavalisse (fostamatinib disodium hexahydrate) Receives FDA Approval for Chronic Immune Thrombocytopenia (ITP) in Adults

 Rigel Pharmaceuticals’ Tavalisse (fostamatinib disodium hexahydrate) Receives FDA Approval for Chronic Immune Thrombocytopenia (ITP) in Adults

Rigel Pharmaceuticals’ Tavalisse (fostamatinib disodium hexahydrate) Receives FDA Approval for Chronic Immune Thrombocytopenia (ITP) in Adults

Shots:

  • The approval is based on three FIT studies results assessing Tavalisse (100/150mg, bid) vs Placebo in 150 patients with chronic ITP in ratio 2:1
  • The FIT studies result: FIT-1 (NCT02076399) stable platelets response (SPR) (18% vs 0%); FIT-2 (NCT02076412) SPR (16% vs 4%); FIT-3 (23%)
  • Tavalisse (fostamatinib disodium hexahydrate, PO) is a spleen tyrosine kinase (SYK) inhibitor and has received OD designation in Jan,2018

Click here to read full press release/ article | Ref: Rigel | Image: Glassdoor

Vartika Singh

Vartika Singh is a content writer who loves to write research articles and reports at PharmaShots. She has in-depth knowledge of the life sciences industry including the Pharma and Biotech sectors. Any articles written by her can be contacted at connect@pharmashots.com.

Related post